Janssen Therap Drug Patent Portfolio
Janssen Therap owns 1 orange book drug protected by 2 US patents Given below is the list of Janssen Therap's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8546428 | Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol | 19 Mar, 2029 | Active |
| US7498343 | Mycobacterial inhibitors | 01 Dec, 2026 | Active |
Latest Legal Activities on Janssen Therap's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Janssen Therap.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Mar, 2021 | US8546428 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Aug, 2020 | US7498343 |
|
Patent Term Extension Certificate
Critical
| 04 Apr, 2017 | US7498343 |
| Notice of Final Determination -Eligible | 07 Dec, 2016 | US7498343 |
|
FDA Final Eligibility Letter
Critical
| 29 Jul, 2016 | US7498343 |
| transaction for FDA Determination of Regulatory Review Period | 28 Dec, 2015 | US7498343 |
| transaction for FDA Determination of Regulatory Review Period | 10 Dec, 2015 | US7498343 |
| Second letter to regulating agency to determine regulatory review period | 13 Mar, 2015 | US7498343 |
| Letter from FDA or Dept of Agriculture re PTE application | 27 Mar, 2014 | US7498343 |
| Initial letter Re: PTE Application to regulating agency | 21 Feb, 2014 | US7498343 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 01 Oct, 2013 | US8546428 |
|
Recordation of Patent Grant Mailed
Critical
| 01 Oct, 2013 | US8546428 |
|
Email Notification
Critical
| 12 Sep, 2013 | US8546428 |
|
Issue Notification Mailed
Critical
| 11 Sep, 2013 | US8546428 |
|
Application Is Considered Ready for Issue
Critical
| 27 Aug, 2013 | US8546428 |
Janssen Therap Drug Patents' Oppositions Filed in EPO
Janssen Therap drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 15, 2013, by Gallafent, Antony Xavier. This opposition was filed on patent number EP07847697A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP07847697A | Feb, 2013 | Gallafent, Antony Xavier | Opposition rejected |
Janssen Therap's Family Patents
Janssen Therap Drug List
Given below is the complete list of Janssen Therap's drugs and the patents protecting them.
1. Sirturo
Sirturo is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8546428 | Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol |
19 Mar, 2029
(4 years from now)
| Active |
| US7498343 | Mycobacterial inhibitors |
01 Dec, 2026
(1 year, 11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sirturo's drug page